NEWYou can now listen to Fox News articles!
AstraZeneca said on Monday that two of its existing therapies were recommended to treat patients with certain forms of high-risk breast cancer in the European Union, to bolster the company’s oncology portfolio.
Lynparza, a cancer drug jointly developed with US-based Merck, has been supported for use on its own or in combination with endocrine therapy in adults with a genetically mutated form of early-stage breast cancer.
The drug, which received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It has been recommended for patients with low to normal levels of a protein known as HER2 which is the target of several new therapies.
ASTRAZENECA TO BUY ALEXION FOR $39 BILLION TO EXPAND IN IMMUNOLOGY
Enhertu, jointly developed with Japanese Daiichi Sankyo, was the other drug approved by the European Medicines Agency for the treatment of an aggressive form of breast cancer characterized by high levels of HER2.
ASTRAZENECA SEES $4B IN COVID-19 VACCINE SALES
Enhertu is seen as a major growth driver for AstraZeneca, with some analysts expecting sales spikes of $10 billion. The drug is also expected to be authorized for patients with low levels of HER2 this month following a recent successful trial.